Urachal and Urethral Cancer (Excluding Penile Cancer)
1. Tumour located in the bladder dome 2. Predominant invasion of the muscularis or deeper with a sharp demarcation between the tumour and surface bladder urothelium that is free of…
Surgical and Minimally Invasive Management of Upper Urinary Tract Tumours
Fig. 37.1 Large filling defect on cross-sectional contrast enhanced CT urography that was proven transitional cell carcinoma Fig. 37.2 Grossly hydronephrotic right kidney with a thin rim of cortex on…
Non-Urological Cancers Affecting the Urinary Tract
Cervix (%risk nodal metastases) Cervix (%risk nodal metastases) IA Microscopic disease confined to the cervix IA1 1 – ≤3 mm deep, ≤7 mm wide (<2 %) IA2 2 – 3–5…
Palliative Care in Urological Cancer
Fig. 15.1 Appropriate care near the end of life (Adapted from Lynn and Adamson [34]. With permission from RAND Corporation) Recently published research in patients with metastatic non-small cell lung…
Cancer Penis and Scrotum
T – Primary tumor TX Primary tumor cannot be assessed TO No evidence of primary tumor Tis Carcinoma in situ Ta Noninvasive verrucous carcinoma TI Tumor invades subepithelial connective tissue…
Castrate Resistant Prostate Cancer: Systemic Chemotherapy and a System Problem
Parameter Raghavan et al. [16] Tannock et al. [14] Kantoff et al. [17] Ernst et al. [18] Berry et al. [19] Raghavan et al. [20] Age Median 64 69 72…
Management of Locally Advanced Prostate Cancer
© Springer-Verlag London 2015Vinod H. Nargund, Derek Raghavan and Howard M. Sandler (eds.)Urological Oncology10.1007/978-0-85729-482-1_47 47. Management of Locally Advanced Prostate Cancer Elaine T. Lam1 and L. Michael Glodé1 (1) Division of Medical Oncology, Department of Medicine, University of Colorado, Aurora,…
Surgical Aspects of Prostate Cancer Management
1. Patients with previous abdominal/pelvic surgery 2. High body mass index 3. Previous prostatic surgery 4. Kidney transplantation/mesh abdominal repair The proponents of RPP describe it as procedure that provides…
External Beam Radiation Therapy for Clinically Localized Prostate Cancer
Risk group Combination of pretreatment variables Low ≤T2a and PSA ≤10 ng/ml and GS ≤6 Intermediate T2b or PSA 10.1–20 ng/ml or GS = 7 High ≥T2c or PSA >20 ng/ml or…
Expectant Management of Localized Prostate Cancer
© Springer-Verlag London 2015Vinod H. Nargund, Derek Raghavan and Howard M. Sandler (eds.)Urological Oncology10.1007/978-0-85729-482-1_41 41. Expectant Management of Localized Prostate Cancer Maria Carmen Mir1 and Andrew J. Stephenson2 (1) Department of Urology, Cleveland Clinic, Cleveland, OH, USA (2) Glickman Urological…
